Does PALBOCICLIB Cause Malignant neoplasm progression? 1,765 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 1,765 reports of Malignant neoplasm progression have been filed in association with PALBOCICLIB (Ibrance). This represents 1.9% of all adverse event reports for PALBOCICLIB.
1,765
Reports of Malignant neoplasm progression with PALBOCICLIB
1.9%
of all PALBOCICLIB reports
216
Deaths
238
Hospitalizations
How Dangerous Is Malignant neoplasm progression From PALBOCICLIB?
Of the 1,765 reports, 216 (12.2%) resulted in death, 238 (13.5%) required hospitalization, and 47 (2.7%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PALBOCICLIB. However, 1,765 reports have been filed with the FAERS database.
What Other Side Effects Does PALBOCICLIB Cause?
Fatigue (15,190)
White blood cell count decreased (11,273)
Neoplasm progression (10,885)
Death (8,410)
Nausea (8,189)
Neutropenia (6,423)
Alopecia (6,201)
Diarrhoea (5,635)
Asthenia (3,660)
Off label use (3,405)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which PALBOCICLIB Alternatives Have Lower Malignant neoplasm progression Risk?
PALBOCICLIB vs PALIPERIDONE
PALBOCICLIB vs PALIVIZUMAB
PALBOCICLIB vs PALONOSETRON
PALBOCICLIB vs PAMIDRONATE
PALBOCICLIB vs PAMIDRONIC ACID